Log in

CNSX:KBBKaneh Bosm Biotechnology Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume3.33 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kaneh Bosm Biotechnology Inc., formerly Anexco Resources Ltd., operates in the cannabis sector. The Company focuses on the deployment of kiosks to ultimate retail locations, and is evaluating various gold and lithium mining assets for potential acquisition. The Company is focused on identifying, acquiring and developing projects with a focus on precious metals deposits. The Company entered into a purchase agreement with Alps Innovations Group Inc. for North and South American rights to an intelligent automated retail kiosk, the BioCanna ADM Automated Cannabis retail system, for the dispensing of cannabis and related products in both medical and commercial markets (the Agreement). BioCanna ADM system is an automated dispensing machine, which is a hybrid between a bank automatic teller machine (ATM), and an intelligent retail kiosk. It operates its engineering, procurement and construction (EPC) division, a full-service engineering, procurement and construction service.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.68 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
WebN/A
Phone+1-604-2831722

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive KBB News and Ratings via Email

Sign-up to receive the latest news and ratings for KBB and its competitors with MarketBeat's FREE daily newsletter.

Kaneh Bosm Biotechnology (CNSX:KBB) Frequently Asked Questions

Has Kaneh Bosm Biotechnology been receiving favorable news coverage?

News headlines about KBB stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kaneh Bosm Biotechnology earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutKaneh Bosm Biotechnology.

What other stocks do shareholders of Kaneh Bosm Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaneh Bosm Biotechnology investors own include Jubilee Metals Group (JLP), DDD Group (DDD), Clontarf Energy (CLON) and Advfn (AFN).

Who are Kaneh Bosm Biotechnology's key executives?

Kaneh Bosm Biotechnology's management team includes the following people:
  • Michael Martinz, President, Director
  • Rudy de Jonge, Chief Executive Officer, Director
  • Anthony Jackson, Chief Financial Officer (Age 34)
  • Kent Ausburn Ph.D., Chief Operating Officer, Director
  • Matthew Wyatt Lechtzier, Director (Age 53)

What is Kaneh Bosm Biotechnology's stock symbol?

Kaneh Bosm Biotechnology trades on the CNSX under the ticker symbol "KBB."

How do I buy shares of Kaneh Bosm Biotechnology?

Shares of KBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How can I contact Kaneh Bosm Biotechnology?

Kaneh Bosm Biotechnology's mailing address is 675 Hastings St W Suite 810, VANCOUVER, BC V6B 1N2, Canada. The company can be reached via phone at +1-604-2831722.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.